AtheroGenics Inc. (AGIX) Announces Clinical Trial Results for Treatment of Type 2 Diabetes
AtheroGenics Inc. (NASDAQ: AGIX) today announced its “topline” results from an interim analysis of its ANDES Phase 3 clinical trial of AGI-1067, for the treatment of Type 2 diabetes, administered once daily for the duration of six months. According to the press release, the primary efficacy endpoint is changed in hemoglobin A1c (A1c) from baseline compared to placebo in patients with Type 2 diabetes. For three months, 806 patients took part in the study, showing dose-related, statistically significant reductions in A1c. For patients receiving 150 mg, 75 mg and a placebo, arms were 0.5 percent, 0.3 percent, and 0.1 percent,…